2018 Update of the EULAR recommendations for the management of large vessel vasculitis.

Hellmich, Bernhard; Agueda, Ana; Monti, Sara; Buttgereit, Frank; de Boysson, Hubert; Brouwer, Elisabeth; Cassie, Rebecca; Cid, Maria C; Dasgupta, Bhaskar; Dejaco, Christian; Hatemi, Gulen; Hollinger, Nicole; Mahr, Alfred; Mollan, Susan P; Mukhtyar, Chetan; Ponte, Cristina; Salvarani, Carlo; Sivakumar, Rajappa; Tian, Xinping; Tomasson, Gunnar; ... (2020). 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Annals of the rheumatic diseases, 79(1), pp. 19-30. BMJ Publishing Group 10.1136/annrheumdis-2019-215672

[img] Text
2018_Update_of_the_EULAR.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (620kB) | Request a copy

BACKGROUND

Since the publication of the European League Against Rheumatism (EULAR) recommendations for the management of large vessel vasculitis (LVV) in 2009, several relevant randomised clinical trials and cohort analyses have been published, which have the potential to change clinical care and therefore supporting the need to update the original recommendations.

METHODS

Using EULAR standardised operating procedures for EULAR-endorsed recommendations, the EULAR task force undertook a systematic literature review and sought opinion from 20 experts from 13 countries. We modified existing recommendations and created new recommendations.

RESULTS

Three overarching principles and 10 recommendations were formulated. We recommend that a suspected diagnosis of LVV should be confirmed by imaging or histology. High dose glucocorticoid therapy (40-60 mg/day prednisone-equivalent) should be initiated immediately for induction of remission in active giant cell arteritis (GCA) or Takayasu arteritis (TAK). We recommend adjunctive therapy in selected patients with GCA (refractory or relapsing disease, presence of an increased risk for glucocorticoid-related adverse events or complications) using tocilizumab. Methotrexate may be used as an alternative. Non-biological glucocorticoid-sparing agents should be given in combination with glucocorticoids in all patients with TAK and biological agents may be used in refractory or relapsing patients. We no longer recommend the routine use of antiplatelet or anticoagulant therapy for treatment of LVV unless it is indicated for other reasons.

CONCLUSIONS

We have updated the recommendations for the management of LVV to facilitate the translation of current scientific evidence and expert opinion into better management and improved outcome of patients in clinical practice.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology, Clinical Immunology and Allergology

UniBE Contributor:

Villiger, Peter

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0003-4967

Publisher:

BMJ Publishing Group

Language:

English

Submitter:

Marlise Bühler Zimmermann

Date Deposited:

23 Dec 2020 15:51

Last Modified:

23 Dec 2020 15:51

Publisher DOI:

10.1136/annrheumdis-2019-215672

PubMed ID:

31270110

Uncontrolled Keywords:

Eular recommendations Takayasu arteritis giant cell arteritis large vessel vasculitis management

BORIS DOI:

10.48350/149775

URI:

https://boris.unibe.ch/id/eprint/149775

Actions (login required)

Edit item Edit item
Provide Feedback